Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03186430 · ClinicalTrials.gov registry record · NA

PreTeenVax Evaluation

A NA study of Human Papilloma Virus, sponsored by Emory University.

Completed
Registry status
NA
Development phase
168
Enrollment target
6
Study locations

NCT03186430 is a NA study of Human Papilloma Virus that has completed, run by Emory University. The registered enrollment target is 168 participants, below the 618-participant average among 26 other Human Papilloma Virus trials with a reported enrollment target (73% lower). The trial reports 6 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03186430, a NA study of Human Papilloma Virus, has completed, sponsored by Emory University.

COMPLETED
Registry status
NA
Development phase
168 participants
Enrollment target
6
Study locations

Study Summary

The primary research aim of this project is to test the effectiveness of a comprehensive, evidence-based vaccine promotion toolkit implemented in the pediatric healthcare setting on increasing the likelihood that adolescents in Georgia will initiate and complete the Human Papillomavirus (HPV) vaccine series. Secondary research aims include assessing the impact of the comprehensive toolkit on 1) patient and parent knowledge and attitudes regarding HPV vaccine, and 2) provider recommendation of HPV vaccine for males and females in the recommended age range (11-12 years). The intervention toolkit will include evidence-based components aimed at the practice-level, provider-level and parent-level that will be tested through a cluster-randomized trial design. The primary hypothesis is that implementation of the comprehensive vaccine promotion toolkit in the pediatric health care setting will increase the likelihood that an adolescent receives initiates HPV vaccination. At the initial visit, parents of adolescent patients at participating pediatric practices will complete a brief questionnaire assessing their knowledge, attitudes, and beliefs about adolescent health, including protection against infectious diseases during adolescence. The parents will be contacted again three months later to complete a short follow-up interview on the general health of their adolescent child, immunization status, and attitudes regarding vaccination.

Conditions Studied

Interventions

  • BEHAVIORAL Comprehensive Vaccine Promotion Package

Study Locations (6)

Georgia

  • DV Pediatrics - Canton
  • Crescent Pediatrics - Duluth
  • Lawrenceville Pediatrics - Lawrenceville Office - Lawrenceville
  • West Atlanta Pediatrics - Lithia Springs
  • Lawrenceville Pediatrics - Loganville Office - Loganville
  • Northlake Pediatric Associates - Stone Mountain

Trial Details

FieldValue
Enrollment Target 168 participants
Start Date 2017-06-14
Est. Completion 2018-07-31
Phase NA

Sponsor

Emory University

1,208 total trials

What the Registry Record Tells You About NCT03186430

The ClinicalTrials.gov registry entry for NCT03186430 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 618-participant average among 26 other Human Papilloma Virus trials with a reported enrollment target (73% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Human Papilloma Virus appearing as the primary indexed condition, and to 1 intervention - of which Comprehensive Vaccine Promotion Package is the first listed.

NCT03186430 reports 6 study locations spanning 1 distinct geographic area - top geographies include Georgia.

Frequently Asked Questions

What is clinical trial NCT03186430 about?

NCT03186430 is a clinical study titled "PreTeenVax Evaluation". The primary research aim of this project is to test the effectiveness of a comprehensive, evidence-based vaccine promotion toolkit implemented in the pediatric healthcare setting on increasing the likelihood that adolescents in Georgia will initiate and complete the Human Papillomavirus (HPV) vaccin...

What is the current status of trial NCT03186430?

This trial is currently completed. It is a NA study. The enrollment target is 168 participants. The study started on 2017-06-14. Estimated completion is 2018-07-31.

What conditions does trial NCT03186430 study?

This clinical trial studies the following conditions: Human Papilloma Virus.

What interventions are being tested in trial NCT03186430?

The interventions under investigation include: Comprehensive Vaccine Promotion Package (BEHAVIORAL).

Who is sponsoring clinical trial NCT03186430?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03186430 being conducted?

This trial has 6 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Human Papilloma Virus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.